ACAD vs OPCH
ACADIA Pharmaceuticals Inc. vs Option Care Health — AI-powered side-by-side comparison
ACAD
ACADIA Pharmaceuticals Inc.
62
Buy
VS
OPCH
Option Care Health
64
Buy
| Metric | ACAD | OPCH |
|---|
| AI Score |
62
|
64
|
| Price |
$29.53
|
$23.70
|
| P/E Ratio |
13.11×
|
17.82×
|
| ROE |
31.9%
|
15.7%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
91.1%
|
18.2%
|
| Debt / Equity |
0.06×
|
1.01×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
59.6
|
55.8
|
| Beta |
0.845
|
0.606
|
| Expected Upside |
—
|
+2.4%
|
AI Committee View
Current Innellis committee reasoning for ACAD versus OPCH.
OPCH leads by 2 points.
OPCH scores 64/100 (Buy) versus ACAD at 62/100 (Buy).
ACAD Committee View
60% agreement
5 analysts
The committee is genuinely divided. Growth Analyst sees a compelling case — quarter-over-quarter growth rate is accelerating, not just positive. Risk Analyst remains cautious — bollinger bandwidth of 22.8% signals elevated volatility. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- Bollinger bandwidth of 22.8% signals elevated volatility — Risk
OPCH Committee View
83% agreement
6 analysts
The primary driver is news sentiment is positive (+0.50 across 4 articles, 14d). The main limiting factor is macd histogram negative -- bearish momentum. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 15.8% shows genuine earnings power backing the valuation — Value
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- News sentiment is positive (+0.50 across 4 articles, 14d) — News
Bear Case
- MACD histogram negative -- bearish momentum — Technical